Duska LR - Search Results

1

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.

Ring KL, Duska LR. Ring KL, et al. Among authors: duska lr. Gynecol Oncol. 2024 May;184:8-15. doi: 10.1016/j.ygyno.2024.01.008. Epub 2024 Jan 24. Gynecol Oncol. 2024. PMID: 38271774 Review.

2

Phase II trial of anastrozole in women with asymptomatic müllerian cancer.

del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. del Carmen MG, et al. Among authors: duska lr. Gynecol Oncol. 2003 Dec;91(3):596-602. doi: 10.1016/j.ygyno.2003.08.021. Gynecol Oncol. 2003. PMID: 14675683 Clinical Trial.

3

When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.

Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N. Duska LR, et al. Gynecol Oncol. 2010 Mar;116(3):374-7. doi: 10.1016/j.ygyno.2009.10.069. Gynecol Oncol. 2010. PMID: 19922988

4

It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters.

Henretta MS, Anderson CL, Angle JF, Duska LR. Henretta MS, et al. Among authors: duska lr. Gynecol Oncol. 2011 Nov;123(2):342-5. doi: 10.1016/j.ygyno.2011.07.031. Epub 2011 Aug 15. Gynecol Oncol. 2011. PMID: 21840583

5

Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?

Ferriss JS, Ring K, King ER, Courtney-Brooks M, Duska LR, Taylor PT. Ferriss JS, et al. Among authors: duska lr. Int J Gynecol Cancer. 2012 Jun;22(5):762-9. doi: 10.1097/IGC.0b013e31824b403d. Int J Gynecol Cancer. 2012. PMID: 22426409

6

The Patient Protection and Affordable Care Act: what every provider of gynecologic oncology care should know.

Duska LR, Engelhard CL. Duska LR, et al. Gynecol Oncol. 2013 Jun;129(3):606-12. doi: 10.1016/j.ygyno.2013.02.036. Epub 2013 Mar 13. Gynecol Oncol. 2013. PMID: 23500090 Review.

7

The Patient Protection and Affordable Care Act: impact on the care of gynecologic oncology patients in the absence of Medicaid expansion in central Virginia.

Courtney-Brooks M, Pelkofski EB, Engelhard CL, Duska LR. Courtney-Brooks M, et al. Among authors: duska lr. Gynecol Oncol. 2013 Aug;130(2):346-9. doi: 10.1016/j.ygyno.2013.04.468. Epub 2013 May 3. Gynecol Oncol. 2013. PMID: 23648470

8

Preoperative imaging of uterine malignancy: A low-value service.

Baker W, Pelkofski E, Te Paske J, Erickson S, Duska L. Baker W, et al. Gynecol Oncol. 2015 May;137(2):285-90. doi: 10.1016/j.ygyno.2015.02.015. Epub 2015 Feb 25. Gynecol Oncol. 2015. PMID: 25724793

9

Uterine carcinosarcoma: A review of the literature.

Cantrell LA, Blank SV, Duska LR. Cantrell LA, et al. Among authors: duska lr. Gynecol Oncol. 2015 Jun;137(3):581-8. doi: 10.1016/j.ygyno.2015.03.041. Epub 2015 Mar 21. Gynecol Oncol. 2015. PMID: 25805398 Review.

10

Lean methodology improves efficiency in outpatient academic Gynecologic Oncology clinics.

Duska LR, Mueller J, Lothamer H, Pelkofski EB, Novicoff WM. Duska LR, et al. Gynecol Oncol. 2015 Sep;138(3):707-11. doi: 10.1016/j.ygyno.2015.07.001. Epub 2015 Jul 15. Gynecol Oncol. 2015. PMID: 26188333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters